3/28
10:05 am
axsm
Rating for AXSM
Report
Rating for AXSM
3/28
10:05 am
axsm
Rating for AXSM
Report
Rating for AXSM
3/26
08:08 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
3/26
08:08 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
3/26
07:33 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
3/26
07:33 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
3/20
08:08 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
3/19
08:10 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $108.00 price target on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $108.00 price target on the stock.
3/19
04:46 am
axsm
Rating for AXSM
Medium
Report
Rating for AXSM
3/19
04:46 am
axsm
Rating for AXSM
Medium
Report
Rating for AXSM
3/4
08:06 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
2/27
10:40 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/27
10:40 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/21
12:55 pm
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/21
12:55 pm
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/21
10:07 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/21
10:07 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/21
09:36 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/20
01:11 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $108.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $108.00 price target on the stock.
2/20
12:31 pm
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/16
06:45 pm
axsm
Rating for AXSM
High
Report
Rating for AXSM
2/16
06:45 pm
axsm
Rating for AXSM
High
Report
Rating for AXSM
2/6
07:48 am
axsm
Rating for AXSM
Low
Report
Rating for AXSM
2/6
07:14 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $111.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $111.00 price target on the stock.
1/25
07:10 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $126.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $126.00 price target on the stock.